Physician profile
Maeve E Oconnor
NPI 1114956752
$2,162,105.66
in general payments reported to CMS, 2019-2025
49 companies · $648K in 2025
The $648K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $100K · 2020: $105K · 2021: $127K · 2022: $231K · 2023: $490K · 2024: $462K · 2025: $648K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $645K · Consulting Fee: $541K · Travel and Lodging: $203K · Honoraria: $174K · Food and Beverage: $37K · Education: $62.14 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $645,054.51 |
| Consulting Fee | $540,890.85 |
| Travel and Lodging | $202,674.55 |
| Honoraria | $173,525.00 |
| Food and Beverage | $37,156.41 |
| Education | $62.14 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $465,119.44 | 2019-2025 | Nucala, Trelegy Ellipta |
| Consortium of Independent Immunology Clinics, LLC | $309,140.84 | 2024-2025 | |
| Genzyme Corporation | $263,206.27 | 2019-2025 | |
| Blueprint Medicines Corporation | $179,199.50 | 2021-2025 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $172,597.36 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Pharming Healthcare, INC. | $162,854.41 | 2019-2025 | Ruconest, Joenja |
| Regeneron Healthcare Solutions, INC. | $97,916.94 | 2019-2025 | Dupixent |
| Optinose US, INC. | $84,685.64 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $71,103.89 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $71,103.82 | 2021-2024 | Orladeyo |
| Csl Behring | $48,084.18 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Teva Pharmaceuticals USA, INC. | $39,938.97 | 2019-2024 | Airduo Digihaler, Armonair Digihaler, Proair Digihaler |
| Grifols USA, LLC | $39,668.45 | 2020-2025 | Xembify, Gamunex-C, Prolastin-C Liquid |
| Adma Biomanufacturing LLC | $22,949.06 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $20,630.31 | 2019-2025 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $17,664.67 | 2020-2022 | |
| Ionis Pharmaceuticals, INC. | $13,957.56 | 2025 | Dawnzera |
| Amgen INC. | $13,306.76 | 2021-2025 | Tezspire, Actimmune |
| Abbvie INC. | $12,204.56 | 2020-2023 | |
| Hikma Pharmaceuticals USA | $11,597.30 | 2021-2023 | Ryaltris |
| Biocryst Pharmaceuticals, INC. | $9,680.81 | 2019-2020 | |
| Shire North American Group INC | $8,455.96 | 2019 | |
| Pfizer INC. | $7,724.69 | 2019-2024 | |
| Octapharma USA, INC. | $3,764.39 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $3,084.00 | 2025 | Dupixent |
| Incyte Corporation | $2,558.71 | 2022-2023 | Opzelura |
| Takeda Pharmaceuticals U.S.A., INC. | $2,450.70 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Aquestive Therapeutics, INC. | $2,275.00 | 2025 | |
| Genentech USA, INC. | $1,351.95 | 2019-2025 | Xolair |
| Alk-Abello, INC | $1,050.07 | 2019-2021 | |
| Sanofi US Services INC. | $785.00 | 2019-2025 | |
| Horizon Therapeutics Plc | $457.18 | 2019-2022 | |
| Kaleo, INC. | $239.75 | 2019-2022 | |
| Circassia INC. | $214.51 | 2020-2022 | |
| Gc Biopharma USA, INC. | $189.75 | 2025 | Alyglo |
| Tersera Therapeutics LLC | $176.06 | 2021-2022 | |
| Grifols Shared Services North America, INC. | $147.33 | 2023-2025 | Xembify |
| Sanofi-Aventis U.S. LLC | $106.70 | 2019-2021 | |
| Verona Pharma, INC. | $95.00 | 2025 | Ohtuvayre |
| Dermavant Sciences, INC. | $68.29 | 2024 | Vtama |
| Strata Skin Sciences, INC. | $62.51 | 2020-2021 | |
| Jubilant Hollisterstier LLC | $59.85 | 2025 | |
| Leo Pharma INC. | $47.60 | 2022 | |
| Genentech, INC. | $40.96 | 2021-2024 | Xolair |
| Covis Pharma Gmbh | $24.82 | 2022 | |
| Merck Sharp & Dohme LLC | $17.98 | 2023 | |
| Uswm, LLC | $17.00 | 2021 | |
| Vyera Pharmaceuticals, LLC | $16.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,707.51 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$8,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maeve Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.